FAIR had the great opportunity to present its objectives and preliminary findings in a full symposium at the European Respiratory Society (ERS) Congress in Vienna, Austria from September 7-11, 2024.
Flagellin aerosol therapy as an immunomodulatory adjunct to the antibiotic treatment of drug-resistant bacterial pneumonia (FAIR) will present a symposium at this year’s ERS Congress, from 7-11 September, in Vienna, Austria.
The first webinar of the FAIR consortium entitled Targeted immunomodulation in airway epithelium to treat pneumonia, took place on 12 January, 2023.
The FAIR project, which aimed to pave the way for the first-in-human phase I clinical trial with nebulized flagellin, is now entering the final stage after a successful 18 months of progress.
